Metastatic pancreatic ductal adenocarcinomas (PDAC) are incurable due to the rapid development of resistance to all current therapeutics. Oncolytic adenoviral mutants have emerged as a promising new strategy that negates such resistance. In contrast to normal tissue, the majority of PDAC express the v6-integrin receptor. To exploit this feature, we modified our previously reported oncolytic adenovirus, Ad∆∆ to selectively target v6-integrins to facilitate systemic delivery. Structural modifications to Ad∆∆ include the expression of the small but potent v6-binding peptide, A20FMDV2 and ablation of binding to the native Coxsackie and Adenovirus Receptor (CAR) within the fibre knob region. The resultant mutant, Ad-3∆-A20T infected and killed v6-integrin expressing cells more effectively than the parental wild type (Ad5wt) virus and Ad∆∆. Viral uptake through v6-integrins rather than native viral receptors (CAR, v3-and v5-integrins) promoted viral propagation and spread. Superior efficacy of Ad-3∆-A20T compared to Ad5wt was demonstrated in 3D organotypic co-cultures, and similar potency between the two viruses was observed in Suit-2 in vivo models. Importantly, Ad-3∆-A20T infected pancreatic stellate cells at low levels, which may further facilitate viral spread and cancer cell elimination either as a single agent or in combination with the chemotherapy drug, gemcitabine. We demonstrate that Ad-3∆-A20T is highly selective for v6-integrin expressing pancreatic cancer cells and with further development, this new and exciting strategy can potentially be extended to improve the systemic delivery of adenoviruses to pancreatic cancer patients.
Introduction
Pancreatic ductal adenocarcinomas (PDAC) are aggressive cancers with high mortality and low 5-year survival rates globally (1) . Major reasons for the dismal prognosis are the late presentation of symptoms and the rapid development of resistance to all current therapeutics that do not significantly prolong survival (1, 2) .
Replication-selective oncolytic adenoviruses efficiently target all epithelial cancers including treatment-resistant pancreatic cancer cells and have excellent safety records in early phase clinical trials. The first oncolytic adenoviral mutant to be evaluated in pancreatic cancer patients was Onyx-015 (dl1520) with deletion of the E1B55K gene enabling virus-propagation in cancer cells with aberrant nuclear mRNA export and non-functional p53 (3) (4) (5) . Despite proven safety in two Phase I trials in conjunction with gemcitabine, efficacy was limited because essential viral functions were compromised by the deletion. More recently, mutants with higher efficacy have been developed by deleting the small pRb-binding E1ACR2-region (∆CR2) that prevent replication in normal tissue while viral propagation and spread in tumour cells is complemented by deregulated cell cycle control (pRb-p16 regulation) (6) (7) (8) . The most common genetic alterations in pancreatic cancer are activating KRAS mutations, CDKN2A/p16 deletion, and inactivating TP53 mutations (9) and consequently, replication of E1A∆CR2 mutants readily proceeds. E1A∆CR2 mutants have not yet been evaluated in PDAC patients while promising outcomes were reported in gliomas and osteosarcomas with Ad5∆CR2-variants (8, 10) .
We recently developed the novel mutant Ad∆∆ with the anti-apoptotic E1B19K gene deleted in addition to the E1ACR2-deletion (6, 11, 12) . E1B19K is a functional Bcl-2 homologue that binds Bax and Bak, and inhibits mitochondrial pore formation and apoptosis in response to death receptor-activation and intrinsically induced apoptosis (13) . Ad∆∆ synergized with the current clinical standard of care for pancreatic cancer, gemcitabine and irinotecan, without toxicity to normal cells (6, 11, 14) . However, to efficiently target pancreatic cancer lesions in patients by systemic administration required further modifications. Human erythrocytes express high levels of the native viral receptor, Coxsackie and Adenovirus Receptor (CAR) and Complement Receptor 1 (CR-1) that bind the viral fibre knob in the presence of neutralizing antibodies and complement, resulting in lower doses of virus reaching the tumour (15) . Other barriers to systemic delivery are the rapid elimination of virus by hepatic Kupffer cells and hepatocyte uptake, and the high affinity binding to numerous blood factors (16) (17) (18) . For example, Factor X (FX) binds to the viral hexon protein and bridges the virus to heparan sulfate proteoglycans (HSPGs) mainly on the hepatocyte surface and promotes liver transduction (17) . Factor IX (FIX) has also been reported to aid the transduction of hepatocytes although, it remains unclear which viral protein is responsible, and complement-4 binding protein (C4BP) binds to the fibre knob (16, 18) . Importantly, viral binding to blood factors rapidly induces innate immune activation to the vector resulting in systemic inflammatory responses in patients (18, 19) . We hypothesised that the local viral concentration at tumour sites could be increased by, i) targeting of mutants to pancreatic tumours and, ii) decreasing binding to erythrocytes and blood factors. Ultimately, we generated a novel oncolytic adenovirus modified to improve tumour targeting.
The vß6-integrin is highly expressed in many solid tumours but not in normal cells (20) (21) (22) . To take advantage of the selective expression of vß6-integrin in PDAC cells, we previously generated the retargeted wild type mutants Ad5A20 and Ad5A20-477dlTAYT (23, 24) . The mutants were engineered to express a 20 amino acid peptide A20FMDV2 derived from the foot-and-mouth disease virus (FMDV) that selectively binds through an Arg-Gly-Asp (RGD)-domain to vß6 (25, 26) . Ad5-A20477dlTAYT was also modified to reduce CAR and complement binding and partially relieved some of the obstacles with systemic delivery by reducing erythrocyte binding (23, 24) .
In this study we report on the generation of a novel mutant, Ad5-3∆-A20T based on the oncolytic mutant Ad∆∆, with incorporation of the A20FMDV2 peptide, ablation of CAR binding and deletion of E3gp19K, for optimal replication-selectivity, cancer targeting and immune stimulation. Ad5-3∆-A20T potently replicated in and killed cultured PDAC cells, in xenografts in vivo and in 3-dimensional co-culture models with pancreatic stellate cells. Ad5-3∆-A20T was highly efficacious and retained all viral functions necessary for propagation in pancreatic cancer cells also in the presence of gemcitabine. We expect these findings to guide further optimisation of oncolytic adenoviruses for systemic delivery to improve on therapeutic efficacy in patients with pancreatic cancer in conjunction with current treatments.
Materials and Methods

Cell lines and culture conditions
Human pancreatic ductal adenocarcinoma (PDAC) cell lines were used in the study:
BxPC-3, Panc04.03, Capan-2, PANC-1, and MiaPaCa-2 (primary tumours); CFPAC-1 and Capan-1 (liver metastasis), Hs766t (lymph node metastasis) (ATCC, LGC Standards, UK), and Suit-2, PaTu8902 and PaTu8988t (liver metastasis) and PaTu8988s (primary tumour) (Cell Services, Cancer Research UK). The PT45 cells (primary tumour) were a kind gift from Prof H. Kalthoff (Comprehensive Cancer, Campus Kiel, Germany). The hTERT-immortalised human pancreatic stellate cells (PS1) were a kind gift from Prof. H. Kocher (BCI, QMUL, London) (27) . The human embryonic kidney cells HEK293 and JH293 (Cell Services, Cancer Research UK) and the human lung carcinoma cells A549 (LGC Standards, UK) were used for viral production. Cells were grown at 37°C and 5% CO 2 in Dulbecco Modified Eagle's medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin and streptomycin (Penicillin 10000 units/ml, Streptomycin 10mg/ml; P/S) (Sigma-Aldrich, MO). All cell lines were STR-profiled (LGC Standards, UK and Cancer Research UK) and verified to be identical to the profiles reported by the suppliers and to the original vial.
Organotypic 3-dimensional (3D) co-culture models
The development of the 3-dimensional co-culture models (organotypic cultures) for pancreatic adenocarcinoma cells and stromal cells has been previously described in detail elsewhere (27) (28) (29) . Briefly, collagen type I was mixed with Matrigel at different ratios, typically 3:1, in Transwells® (Corning; Sigma-Aldrich) and placed in 24-well plates. Panc0403 or Suit-2 cells were seeded together with PS1 cells (typical ratio 1:2; total 1x10 5 cells/well) on top of gels in 10% FBS Ham's F12/DMEM (GIBCO). After 24h the media in the top-chamber was replaced with serum-free DMEM, 3-4 days later viruses were added at 2-5-fold higher doses than in regular 2D-cultures and fixed in formalin 4-7days later. In some studies cells were embedded within the gels and virus added either in the top or bottom compartment. In combination studies gemcitabine (Gemzar; Eli Lilly, IN) was added at 5-10nM in serum-free DMEM on top of gel and/or in 10% FBS Ham's F12/DMEM underneath the transwell.
Viruses and infections
Wild-type virus Ad5 and the modified EGFP-expressing mutants, Ad5, Ad5A20 and Ad5A20-477dlTAYT were previously generated from species C wild-type adenovirus type 5 (23, 24) . Briefly a 20-amino acid RGD-binding peptide (A20FMDV2;
NAVPNLRGDLQVLAQKVART (26)) from VP1 of the foot-and-mouth disease virus (FMDV) (30) was incorporated in the HI-loop of the Ad5 fibre knob in Ad5A20 (23).
Ad5A20 was further modified to generate Ad5A20-477dlTAYT through a base substitution Y477A and a deletion of amino acids 489-492 (TAYT) in the fibre knob and the E3gp19K gene was replaced by EGFP (18, 24, 31) . Generation of Ad∆∆ (deleted in E1ACR2 and E1B19K) has previously been described (6, 12) . Ad5-3∆-A20477dlTAYT (Ad5-3∆-A20T) was generated by two-step homologous recombination in SW102 bacteria (32, 33) . The wild-type Ad5 genome previously captured within a bacterial artificial chromosome (BAC) was modified in a series of stages (primer sequences; Supplementary Table 1) . First, the wild type E1 genes were replaced with the PCR amplified modified E1-region from Ad∆∆. Next, the fibre knob domain of Ad5A20-477dlTAYT was PCR amplified and inserted to replace the wild-type knob. Finally, the E3gp19K domain was deleted generating Ad5-3∆-A20T.
The viruses were produced, purified and characterised according to standard protocols (6, 12) . The viral particle (vp) to infectious unit (plaque-forming units; pfu) was 9-45vp/pfu for all viruses with the highest ratios for the FMDV expressing mutants. All infections were performed in serum-free DMEM and 2h later the media was replaced with 10% FBS/1% P/S DMEM ± the indicated doses of drugs.
Cell viability assay
Cells were infected with viral mutants in 2% FBS/1% P/S DMEM and were assayed 72h or 96h later using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay (MTS; Promega, Southampton, UK) to quantify live cells as an indirect measurement of cell death. Dose-response curves were generated to determine the concentration of each virus killing 50% of cells (EC 50 ) using untreated cells as controls. Each data point was generated from triplicate samples and experiments repeated at least three times as described previously (12) .
Viral genome amplification by qPCR
Cells were infected with 100 particles per cell (ppc) of the respective virus and were harvested 4, 24, 48 and 72h later. The cell suspensions were pelleted, snap-frozen and stored at -80ºC. DNA was extracted using the QIAamp DNA Blood Mini Kit, according to the manufacturer's instructions (Qiagen, Netherlands) and used for quantitative PCR (qPCR) analysis as previously described (11, 14) .
Viral replication assay by tissue culture infectious dose (TCID 50 )
Cells were infected as described for qPCR and cells and media were collected at the indicated time points, freeze-thawed, and analyzed by the TCID 50 limiting dilution method on JH293 or A549 cells. Ad5 wild type virus of known activity was included in every assay as internal control as previously described (14) .
Quantification of infectivity and cell surface receptor levels
Cells were seeded (1x10 5 cells/well) in 6-well plates 24h prior to infection with the EGFP-expressing mutants at 100 or 500ppc in serum free DMEM, 2h later media was Tumours were harvested at the end of the study and fixed in 4% formaldehyde. The fixed tissues were sectioned and processed for histopathology with hematoxylin and eosin (H/E) and for IHC by staining for E1A and hexon (1:2000; AutogenBioclear)
followed by detection using HRP-conjugated secondary antibodies (Dako).
In vivo tumor growth
Tumor cells were inoculated subcutaneously in one flank of CDnu/nu athymic mice Tumor volumes were estimated twice weekly: volume = (length x width 2 x π)/6 and growth curves were compared using one-way Anova. Survival analysis was performed according to the method of Kaplan-Meier (log rank test for statistical significance). Each treatment group included 8 animals and studies were performed twice according to two protocols as described above. For viral distribution studies, virus was administered via the tail vein with a single injection of 3x10 9 vp in 100µl.
Tumours were harvested 24, 48 and 72h later, sonicated, and protein expression determined by Western blotting (Supplementary Materials and Methods). E1A was detected by mouse anti-E1A (1:500; M58, GeneTex) and PCNA by mouse anti-PCNA (1:1000; Santa Cruz Biotech).
Results
Pancreatic cancer cells express higher levels of vß6-integrin than Coxsackie
Adenovirus Receptor (CAR) and are more susceptible to infection with A20FMDV2-retargeted mutants than with Adwt.
Pancreatic tumours frequently express the vß6-integrin, reported to play a role in the progression of pancreatic cancer (21, 34) . A panel of 15 human pancreatic cancer cell lines was screened for vß6-integrin expression to determine the feasibility of retargeting the replication-selective Ad∆∆ to this integrin. Expression levels were high in the majority of cell lines while levels of the native adenovirus receptor CAR,
were consistently low compared to the JH293 cells ( Table 2 ). Despite higher levels of infection with the retargeted Ad5A20TAYT and Ad5A20 mutants in BxPC-3 cells ( Fig. 2A) it is possible that the lower EC 50 -values for both Adwt and mutants masked small differences in cell killing ability in these cells.
Viral genome amplification is increased with A20FMDV2-expressing mutants in cells
expressing high levels of the vß6-integrin.
In Suit-2 and Panc04.03 cells, the enhanced infection and cell killing with the A20FMDV2-mutants were paralleled by higher levels of viral genome amplification compared to infection with Ad5wt at all time points (24-72h) ( The vß3-and vß5-integrins play a major role in internalisation of Ad5wt, mediated by penton-integrin binding through RGD-interactions. To examine whether these integrins were also essential for the FMDV-retargeted mutants or whether binding to the vß6-integrin alone was sufficient for cellular uptake of virus, we first determined the expression levels of vß3-and vß5-integrins (Fig 3A) . PT45 and Suit2 cells expressed the highest levels of vß5-integrins and BxPC-3 of the vß3-integrin. The greatest expression of vß6-integrins was observed in Suit-2 and Panc04.03 cells.
Blocking of vß6-integrin receptors with free A20FMDV2 peptide significantly decreased the infection levels with Ad5A20 and Ad5A20-477dlTAYT but not with Ad5wt in Panc04.03, Suit-2 and BxPC-3 cells (Fig. 3B) . The most pronounced effect was in Suit-2 and Panc04.03 cells with reductions up to 70% compared to original levels of infection. Decreased E1A-expression in cells infected with Ad5A20-477dlTAYT but not with Ad5wt further confirmed our findings (Panc0403; Supplementary Fig. 1E ). Thus, Ad5A20 and Ad5A20-477dlTAYT were mainly internalised through vß6-integrins in pancreatic cancer cells although, other integrins such as vß5 may contribute towards the process. Importantly, in cells with low or non-detectable levels of vß6-integrins, infection with the retargeted mutants was reduced compared to infection with Ad5wt (Fig. 3A-B and Fig. 1B ). Fig. 4A ; confocal images). The effect was similar in Suit-2 cells although, the inhibition of invasion and growth was less than in Panc04.03 cells ( Fig. 4A; right panels) . Importantly, we demonstrate that the infected epithelial cells were in sufficiently close contact with the PS1 stromal cells for virus to spread through the matrix and infect both cancer and stromal cells (Fig. 4B ).
Viral replication and spread is supported in organotypic 3-dimensional (3D) co
Viral infection and replication in PS1 cells were initially determined in 2-dimensional monocultures (Fig. 4C) . As expected for non-epithelial cells the level of infection was poor with the highest levels for Ad5wt with <10% of cells expressing EGFP, and <5% for the retargeted mutants compared to 20-50% in vß6-integrin-expressing epithelial cancer cells (Fig. 4C and 3B) . Importantly, the early viral E1A gene was expressed at detectable levels in the PS1 monolayers (Supplementary Figure 3A-B ).
Viral uptake was likely mediated by vß3-and vß5-integrins (Fig. 4D) , and was significantly reduced in the presence of an anti-vß5-integrin antibody (Fig 4C) . CAR and the vß6-integrin were not detected in PS1 cells (Fig. 4D) . We tested whether To further exploit the selective targeting to vß6-integrins on pancreatic cancer cells, the A20FMDV2 peptide was inserted and CAR-binding was ablated in the fibre knob (HI-loop) of the Ad∆∆ mutant, to generate Ad5-3∆-A20T ( Fig. 5A and Supplementary Fig. 1B ) (6, 23, 24) . In addition to the E1ACR2 and E1B19K deletions in Ad∆∆ that provide replication-selectivity and apoptosis-enhancement, deletion of the TAYT-motif and the point-mutation at Y477A were included to reduce CAR-binding. These mutations and the insertion of the A20FMDV2 peptide were identical to the alterations in the parental Ad5A20-477dlTAYT mutant (18, 24, 40) ( Fig. 5A and Supplementary Fig. 1B ). The resulting oncolytic mutant Ad5-3∆-A20T killed Panc04.03 and Suit-2 cells more potently than the parental Ad∆∆ mutant demonstrated by 10-and 5-fold lower EC 50 -values ( Fig. 5B; left panel) . In contrast, in PS1 cells that were significantly less sensitive to virus-induced cell killing (>10-fold higher EC 50 -values), the novel mutant had similar cell killing potency as Ad5wt ( Fig.   5B ; right panel). Replication of Ad5-3∆-A20T in Panc04.03 and Suit-2 cells was slightly less than for Ad∆∆ (Fig. 5C ). Replication in PS1 cells was also less for Ad5-3∆-A20T than for Ad∆∆. However, both viruses showed >100-fold lower levels of replication in PS1 than in epithelial cells; Ad5-3∆-A20T replication was 4.2x10 5 ± 2.2x10 5 pfu/ml and Ad∆∆ 1.7x10 7 ± 5.1x10 6 pfu/ml (n=3) 48h post-infection in the stromal cells.
Ad5-3∆-A20T potently inhibits growth and invasion of Panc0403 cells in 3D cocultures with the pancreatic stromal PS1 cells.
Dose-dependent cell killing was observed when 3D co-cultures of Panc04.03-PS1 cells were infected with Ad5-3∆-A20T or Ad∆∆ (500 and 1000ppc) for 4 days (Panc04.03; Fig. 5D ). In cultures infected with Ad5-3∆-A20T, viable and/or invading cells appeared to be fewer than in Ad∆∆-infected cultures at the lower dose, while the higher dose eliminated most cells with both viruses. Importantly, the efficacy of Ad5-3∆-A20T was retained in organotypic co-cultures of Panc04.03 or Suit-2 with PS1 cells when treated simultaneously with gemcitabine (Suit-2; Fig. 5E and Supplementary Fig. 4 ). We previously demonstrated that both Ad∆∆ and Ad∆19K synergised with low doses of gemcitabine in pancreatic cancer cells in 2D monocultures and in vivo, including Suit-2 models, by enhancing apoptotic death through mitotic aberrations (11, 14) . We found that the 3D co-culture system was a suitable model for screening the efficacy of adenoviral mutants and for confirming compatibility with current therapeutic cytotoxic drugs.
Ad5-3∆-A20T efficiently inhibits growth of human pancreatic cancer xenografts in murine models.
The potent elimination of Panc04.03 and Suit-2 cells grown in 2D mono-and 3D cocultures were confirmed in vivo, using Suit-2 xenografts grown subcutaneously in athymic mice. We have previously demonstrated that the Suit-2 model is suitable for determining efficacy of adenoviral mutants administered alone or in combination with cytotoxic drugs (12, 41) . Both Adwt and Ad5-3∆-A20T potently prevented tumor growth up to 20 days after the first administration of virus (Fig. 6A) . From 20-42d growth was greatly reduced compared to the mock-treated animals that were culled already after 18 days due to tumour burden and ulcer formation. The median time to tumor progression was significantly prolonged (p<0.0004) from 11d for mock-treated animals to 42d with Ad5-3∆-A20T and 37d for Adwt (Fig. 6B) . Tumours harvested when animals were culled showed intense E1A expression for both viruses up to 53d after virus-administration (Fig. 6C) . The ultimate goal of generating Ad5-3∆-A20T
was to increase viral dose at tumour lesions after systemic delivery. In this proof-ofconcept study, potent expression of E1A was observed in Suit-2 tumours after a single tail vein administration of Ad5-3∆-A20T (Fig. 6D) . Interestingly, E1A expression appeared to be lower after tail vein injection with Adwt. The results from the 3D cocultures and the in vivo studies demonstrated that Ad5-3∆-A20T was at least as efficacious as Ad5wt under conditions that more realistically mimic the tumour microenvironment in situ in patients. Future studies will be aimed at quantifying the retargeting efficacy in murine models that can mimic the conditions in patients more accurately including systems with humanised blood factors. Taken together our data support further exploration of Ad5-3∆-A20T for potential future development into novel anti-cancer agents targeting pancreatic cancer.
Discussion
No curative treatments are currently available for patients with metastatic PDAC, and resistance to chemotherapeutics inevitably develops. The recent identification of several biomarkers will hopefully enable earlier detection and curative surgery in more patients (42, 43) . In contrast, replication-selective oncolytic adenoviral mutants target pancreatic cancer at any stage by direct oncolysis, reversal of drug resistance and activation of anti-tumour immune responses but have poor efficacy when delivered systemically (8, 10) . The focus of our study was to optimize the potent and selective oncolytic mutant Ad∆∆ (6) to enable future development of this mutant for systemic delivery by taking advantage of the selective expression of vß6-integrin in pancreatic cancer cells. We generated the replication-selective integrin-targeted Ad5-3∆-A20T mutant expressing the small vß6-peptide ligand A20FMDV2. The A20FMDV2 peptide was derived from the GH-loop in VP1 in the capsid of the footand-mouth disease virus (FMDV) and is essential for infection in cloven-hoofed animals (44) . The affinity to vß6-integrins was high, measured at K D =0.22nM, while binding to other integrins, including vß3, vß5 and vß1 was more than 80-fold lower (21, 25) . The selective binding to vß6-integrins was shown to be dependent on the DLXXL motif in the carboxy -helical loop next to the RGD-domain at the apex of the loop domain in the peptide (23, 26, 44, 45) .
We previously demonstrated that the retargeted wild type mutants Ad5A20 and vß6-compared to vß3-and vß5-integrins. Interestingly, pancreatic stellate cells that lack vß6-integrins were infected by Ad5-3∆-A20T, suggesting that uptake in these cells was dependent on other integrins including vß5, in the presence of high local doses of virus. These processes are the subjects for future investigations.
Following the initial proof-of concept studies, the chimeric fiber from Ad5A20-477dlTAYT was engineered into the Ad∆∆ mutant to generate Ad5-3∆-A20T. The additional modifications to the CAR-binding region of the fibre-knob were also retained as a strategy to facilitate systemic delivery in future studies. We previously found that Ad5A20-477dlTAYT had improved liver-to-tumour viral genome ratios possibly through abrogation of FIX/C4BP-binding due to the TAYT-deletion (18, 24) .
Importantly, Ad5A20-477dlTAYT did not agglutinate erythrocytes due to detargeting of CAR through the Y477A mutation. The novel Ad5-3∆-A20T mutant infected and killed vß6-integrin expressing PDAC cells more efficiently than both Despite the rapid hepatic elimination of adenovirus in mice, we confirmed that intravenous delivery of Ad5-3∆-A20T resulted in high levels of viral gene expression in Suit-2 tumours. Future studies will address whether the retargeted mutant will reach tumours in sufficiently high levels to warrant systemic administration.
Importantly, the Suit-2 cells employed in the xenograft studies expressed lower levels of vß6-integrin and higher levels of vß5 compared to Panc04.03 cells. We predict that tumour xenografts with similar integrin-profiles, high vß6-and lower vß3-and vß5-integrin expression, would reflect the higher cell killing seen in vitro.
We optimised the previously developed 3D co-culture models of pancreatic stellate and cancer cell lines (27) (28) (29) , for investigating viral infection and spread in this study.
These models have more similarities with the tumour microenvironment in patients than traditional 2D monocultures. In addition, the interaction with human stromal cells is retained without interference from murine stroma present in athymic mice models. Although, more sophisticated organoid culture models have been described for murine and patient tumour tissue including a few methods for modeling pancreatic cancer (37, 39) , we found that our 3D co-cultures were more suitable for screening of viral functions. We found that both Ad5-3∆-A20T and Ad5A20 were more demonstrated for Ad∆∆ in PDAC cells (6, 11, 12, 14) . We propose that the 3D co- 
